Evidence map›Paper›PMID 23924957›Full record

ArticleKidney international2014

Adventitial transduction of lentivirus-shRNA-VEGF-A in arteriovenous fistula reduces venous stenosis formation.

Binxia Yang, Rajiv Janardhanan, Pawan Vohra, Eddie L Greene, Santanu Bhattacharya, Sarah Withers, Bhaskar Roy, Evelyn C Nieves Torres, Jaywant Mandrekar, Edward B Leof and 2 more

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Kidney international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
9.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02695641 early_phase1withdrawnnot on this mapstarted 2019, after this paper: background citation

A Phase 0 Study to Evaluate the Pharmacokinetics of Low-dose Bevacizumab and Its Efficacy on Reducing Plasma Free Vascular Endothelial Growth Factor-A (VEGF-A) in Hemodialysis Patients

TypeinterventionalSponsorMayo ClinicRan2019 to 2021Enrolled0ConditionsEnd Stage Renal Disease, Hemodialysis Vascular Access FailureArms1.25mg bevacizumab, 2.50mg bevacizumab
NCT06249373 narecruitingnot on this mapstarted 2024, after this paper: background citation

A Multicenter Randomized Controlled Trial on the Effect of Low-intensity Pulsed Ultrasound on the Maturation of Newly Constructed Autogenous Arteriovenous Fistulas in Uremic Patients

TypeinterventionalSponsorSuzhou Municipal HospitalRan2024 to 2026Enrolled300ConditionsUremia, ChronicArmsLow intensity pulse ultrasound (LIPUS) intervention for arteriovenous fistula anastomosis
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Delivery of Nucleic Acids for Vascular Tissue Engineering Applications.Regenerative engineering and translational medicine · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Pulmonary Vascular Remodeling in Pulmonary Hypertension.Journal of personalized medicine · 2023
    Review
  13. Bindarit encapsulated nanoparticles prevent venous neointimal hyperplasia and restenosis in a murine angioplasty model.Translational research : the journal of laboratory and clinical medicine · 2022
    Article
  14. Review
  15. Article
  16. Role and Mechanism of Epithelial-Mesenchymal Transition Mediated by Inflammatory Stress-Induced TGF-Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Binxia YangVascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Rajiv JanardhananVascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Pawan VohraVascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Eddie L GreeneDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
Santanu BhattacharyaVascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Sarah WithersVascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Bhaskar RoyVascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Evelyn C Nieves TorresVascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Jaywant MandrekarDepartment of Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Edward B LeofDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.
Debabrata MukhopadhyayDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.
Sanjay Misra1] Vascular and Interventional Radiology Translational Laboratory, Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA [2] Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic in Arizona · USMayo Clinic · US

Funding

The Role of Hypoxia In Venous Neointimal Hyperplasia In Hemodialysis GraftsR01HL098967 · NHLBI · MAYO CLINIC ROCHESTER · PI Sanjay Misra · 2010 to 2026
$10.4M
TGF BETA RECEPTORS AND CELL PROLIFERATIONR01GM054200 · NIGMS · MAYO CLINIC ROCHESTER · PI LEOF, EDWARD B · 1996 to 2018
$6.1M
TGF Beta Receptor DynamicsR37GM055816 · NIGMS · MAYO CLINIC ROCHESTER · PI LEOF, EDWARD B · 2009 to 2018
$3.6M
NHLBI NIH HHS R01 HL098967NHLBI NIH HHS R01HL098967NIGMS NIH HHS R01 GM054200NIGMS NIH HHS R37 GM055816
6 · The paper itself

Abstract

Venous neointimal hyperplasia (VNH) causes hemodialysis vascular access failure. Here we tested whether VNH formation occurs in part due to local vessel hypoxia caused by surgical trauma to the vasa vasorum of the outflow vein at the time of arteriovenous fistula placement. Selective targeting of the adventitia of the outflow vein at the time of fistula creation was performed using a lentivirus-delivered small-hairpin RNA that inhibits VEGF-A expression. This resulted in significant increase in mean lumen vessel area, decreased media/adventitia area, and decreased constrictive remodeling with a significant increase in apoptosis (increase in caspase 3 activity and TUNEL staining) accompanied with decreased cellular proliferation and hypoxia-inducible factor-1α at the outflow vein. There was significant decrease in cells staining positive for α-smooth muscle actin (a myofibroblast marker) and VEGFR-1 expression with a decrease in MMP-2 and MMP-9. These results were confirmed in animals that were treated with humanized monoclonal antibody to VEGF-A with similar results. Since hypoxia can cause fibroblast to differentiate into myofibroblasts, we silenced VEGF-A gene expression in fibroblasts and subjected them to hypoxia. This decreased myofibroblast production, cellular proliferation, cell invasion, MMP-2 activity, and increased caspase 3. Thus, VEGF-A reduction at the time of arteriovenous fistula placement results in increased positive vascular remodeling.

Indexed as

Genetic VectorsRNA InterferenceTransduction, GeneticAdventitiaAnimalsApoptosisArteriovenous Shunt, SurgicalCarotid ArteriesCaspase 3Cell MovementCell ProliferationCells, CulturedConstriction, PathologicDisease Models, AnimalFibroblastsGenetic TherapyCasp3 protein, mouseCaspase 3Matrix Metalloproteinase 2Matrix Metalloproteinase 9Mmp2 protein, mouseMmp9 protein, mouseRNA, Small InterferingVascular Endothelial Growth Factor Avascular endothelial growth factor A, mouse

Identifiers

PMID23924957
PMCPMC3844094
OpenAlexW2024935147

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.